Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Calithera Biosciences, Inc.CALA · Entity 113073 | Director · PRESIDENT & CEO | January 23, 2023 | January 25, 2023 |
| Cyteir Therapeutics, Inc.CYT · Entity 92707 | Director | February 03, 2023 | February 07, 2023 |
| GERON CORPGERN · Entity 4989 | Director | May 20, 2026 | May 26, 2026 |
| Repare Therapeutics Inc.RPTX · Entity 68433 | Director | June 17, 2024 | June 20, 2024 |
| Theravance Biopharma, Inc.TBPH · Entity 5037 | Director | April 27, 2021 | April 29, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Calithera Biosciences, Inc.
Report date January 23, 2023 · Filed January 25, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 27,859 |
Reported balance
After 2023-01-23 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-01-23 · Tax withholding · Disposed 526 · Balance 27,859 F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on January 23, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. F3: Shares are held by the Molineaux Family Trust of which the Reporting Person is a Trustee. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 5,283 |
Reported balance
Holding disclosure · report date 2023-01-23 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,283 |
| Common StockSEC Table I · non-derivative | Direct | 4,724 |
Reported balance
Holding disclosure · report date 2023-01-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 4,724 F4: Includes 125 shares acquired on each of December 10, 2021, June 10, 2022 and December 9, 2022, under the Company's 2014 Employee Stock Purchase Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on January 23, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
F3: Shares are held by the Molineaux Family Trust of which the Reporting Person is a Trustee.
F4: Includes 125 shares acquired on each of December 10, 2021, June 10, 2022 and December 9, 2022, under the Company's 2014 Employee Stock Purchase Plan.
Cyteir Therapeutics, Inc.
Report date February 03, 2023 · Filed February 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.69 · Expires 2033-02-03 | Direct | 14,150 |
Reported balance
After 2023-02-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-03 · Grant · Acquired 14,150 · Balance 14,150 F1: The shares of common stock underlying this stock option award vest in full on February 3, 2024, subject to the Reporting Person's continued service to the board of directors of the Company through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock underlying this stock option award vest in full on February 3, 2024, subject to the Reporting Person's continued service to the board of directors of the Company through the applicable vesting date.
GERON CORP
Report date May 20, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.26 · Expires 2036-05-19 | Direct | 220,000 |
Reported balance
After 2026-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 220,000 · Balance 220,000 F1: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates.
Repare Therapeutics Inc.
Report date June 17, 2024 · Filed June 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.80 · Expires 2034-06-16 | Direct | 27,200 |
Reported balance
After 2024-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-17 · Grant · Acquired 27,200 · Balance 27,200 F1: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date.
Theravance Biopharma, Inc.
Report date April 27, 2021 · Filed April 29, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 9,828 |
Reported balance
After 2021-04-27 transaction · row 1
1 source rowRow 1 · 2021-04-27 · Grant · Acquired 9,828 · Balance 9,828 |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.35 · Expires 2031-04-26 | Direct | 6,000 |
Reported balance
After 2021-04-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-04-27 · Grant · Acquired 6,000 · Balance 6,000 F1: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Family Trust | 41,206 |
Reported balance
Holding disclosure · report date 2021-04-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 41,206 |
Filing footnotes · ownership attribution and instrument terms
F1: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 05, 2017 Filed Dec 6, 2017 16:05 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 7,568 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0000899243-17-028063 · doc4.xml · derivative · entry 5 Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,568 shares Expires 2023-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments one month from 05/23/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. Read SEC document |
| December 05, 2017 Filed Dec 6, 2017 16:05 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | Exercise / conversionCommon Stock | 5,300 | $2.64 | $13,992.00 |
DisclosureSEC source: 0000899243-17-028063 · doc4.xml · nonDerivative · entry 2 Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,368 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,500 shares acquired under the Company's 2014 Employee Stock Purchase Plan on June 9, 2017. Read SEC document |
| December 05, 2017 Filed Dec 6, 2017 16:05 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | Exercise / conversionCommon Stock | 7,568 | $0.96 | $7,265.28 |
DisclosureSEC source: 0000899243-17-028063 · doc4.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,500 shares acquired under the Company's 2014 Employee Stock Purchase Plan on June 9, 2017. Read SEC document |
| September 29, 2017 Filed Oct 2, 2017 21:32 UTC | GERON CORP GERN · Entity 4989 | GrantCommon Stock | 6,021 | $0.00 | $0.00 |
DisclosureSEC source: 0000886744-17-000042 · edgar.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 73,191 F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on September 29, 2017 of $2.18 per share. F1 · shares: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on September 29, 2017 of $2.18 per share. F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on September 29, 2017 of $2.18 per share. Read SEC document |
| June 30, 2017 Filed Jun 30, 2017 23:48 UTC | GERON CORP GERN · Entity 4989 | GrantCommon Stock | 4,738 | $0.00 | $0.00 |
DisclosureSEC source: 0000886744-17-000036 · edgar.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 67,170 F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on June 30, 2017 of $2.77 per share. F1 · shares: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on June 30, 2017 of $2.77 per share. F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on June 30, 2017 of $2.77 per share. Read SEC document |
| May 17, 2017 Filed May 18, 2017 22:04 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-007543 · edgar.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Read SEC document |
| May 09, 2017 Filed May 11, 2017 00:52 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0000886744-17-000030 · edgar.xml · derivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-05-09 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the company through such dates. Read SEC document |
| March 31, 2017 Filed Mar 31, 2017 23:28 UTC | GERON CORP GERN · Entity 4989 | GrantCommon Stock | 5,782 | $0.00 | $0.00 |
DisclosureSEC source: 0000886744-17-000017 · edgar.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 62,432 F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on March 31, 2017 of $2.27 per share. F1 · shares: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on March 31, 2017 of $2.27 per share. F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on March 31, 2017 of $2.27 per share. Read SEC document |
| December 30, 2016 Filed Jan 4, 2017 00:56 UTC | GERON CORP GERN · Entity 4989 | GrantCommon Stock | 6,341 | $0.00 | $0.00 |
DisclosureSEC source: 0000886744-17-000002 · edgar.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 56,650 F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on December 30, 2016 of $2.07 per share. F1 · shares: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on December 30, 2016 of $2.07 per share. F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on December 30, 2016 of $2.07 per share. Read SEC document |
| December 19, 2016 Filed Dec 20, 2016 09:00 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 4,749 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0000899243-16-036013 · doc4.xml · derivative · entry 8 Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 9,498 Underlying: Common Stock · 4,749 shares Expires 2023-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments one month from 12/17/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. Read SEC document |
| December 19, 2016 Filed Dec 20, 2016 09:00 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,418 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0000899243-16-036013 · doc4.xml · derivative · entry 7 Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 6,502 Underlying: Common Stock · 5,418 shares Expires 2023-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments one month from 05/23/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. Read SEC document |
| December 19, 2016 Filed Dec 20, 2016 09:00 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,627 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0000899243-16-036013 · doc4.xml · derivative · entry 6 Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,021 Underlying: Common Stock · 15,627 shares Expires 2023-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments one month from 12/17/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. Read SEC document |
| December 19, 2016 Filed Dec 20, 2016 09:00 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,306 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0000899243-16-036013 · doc4.xml · derivative · entry 5 Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,568 Underlying: Common Stock · 6,306 shares Expires 2023-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments one month from 05/23/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. Read SEC document |
| December 19, 2016 Filed Dec 20, 2016 09:00 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | Exercise / conversionCommon Stock | 15,627 | $2.64 | $41,255.28 |
DisclosureSEC source: 0000899243-16-036013 · doc4.xml · nonDerivative · entry 2 Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,810 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes1,877 shares acquired under the Company's 2014 Employee Stock Purchase Plan on November 15, 2016. Read SEC document |
| December 19, 2016 Filed Dec 20, 2016 09:00 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | Exercise / conversionCommon Stock | 6,306 | $0.96 | $6,053.76 |
DisclosureSEC source: 0000899243-16-036013 · doc4.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes1,877 shares acquired under the Company's 2014 Employee Stock Purchase Plan on November 15, 2016. Read SEC document |
| November 29, 2016 Filed Dec 1, 2016 16:05 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantEmployee Stock Option (Right to Buy) · Derivative | 165,000 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0000899243-16-034658 · doc4.xml · derivative · entry 1 Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2026-11-28 F1 · derivative.exercise_date: One-fourth (1/4th) of the Option vests one year after November 29, 2016; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. Read SEC document |
| September 30, 2016 Filed Oct 3, 2016 22:59 UTC | GERON CORP GERN · Entity 4989 | GrantCommon Stock | 5,808 | $0.00 | $0.00 |
DisclosureSEC source: 0000886744-16-000071 · edgar.xml · nonDerivative · entry 1 Molineaux Susan · CIK 0001553389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 50,309 F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on September 30, 2016 of $2.26 per share. F1 · shares: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on September 30, 2016 of $2.26 per share. F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on September 30, 2016 of $2.26 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.